The Citizens Commission on Human Rights (CCHR) is urging consumers to carefully read psychiatric drug labels and ask their doctors about potential side effects such as aggression, suicidal thoughts, and homicidal ideation. This call follows recent news reports linking violent crimes to individuals taking or withdrawing from prescribed antidepressants and other psychiatric medications. CCHR argues that even when these effects are labeled as rare, patients must be fully informed of the risks before consenting to treatment.
Jan Eastgate, president of CCHR International, emphasized that a rare warning buried in a package insert is insufficient. “Listing a side effect as ‘rare’ does not establish that the patient was told about it, understood it, or agreed to take that risk,” she said. “Meaningful informed consent requires meaningful disclosure and prescriber accountability.”
The issue has also entered the legal and psychiatric discourse. A recent article in Psychiatric Times titled “Psychiatry on Trial: Are Psychiatrists Responsible for Their Patients’ Criminal Behavior?” discussed a murder case where the defense argued that psychiatric polypharmacy contributed to violent behavior. The journal noted that public and media support for this theory places psychiatrists under scrutiny, and concluded that “psychiatry itself may end up on trial.”
One legal doctrine relevant in such cases is involuntary intoxication, which may apply when a prescribed drug induces violent behavior. However, as Eastgate points out, a judge allowing evidence about prescription drugs is not the same as a physician warning a patient before the first dose. “Psychiatrists must disclose what patients need to make informed decisions,” she added.
The concern is not new. In 2004, the FDA issued a public health advisory on antidepressants, citing reports of anxiety, agitation, hostility, and other behavioral effects. That same year, the FDA mandated a boxed warning about suicidality in children and adolescents, later expanded to young adults. CCHR’s compilation shows a dramatic increase in regulatory warnings: since 2004, there have been 57 warnings involving violence, aggression, or hostility, compared to five in 2004—a 1,040% increase. Thirteen of these specifically reference homicidal ideation.
Specific drug labels illustrate the issue. In 2005, homicidal ideation was added to the label for extended-release venlafaxine. In 2009, the FDA required a boxed neuropsychiatric warning for bupropion products, citing postmarketing reports of hostility, aggression, and homicidal ideation. In 2023, a class-wide warning for stimulants noted that “anxiety, psychosis, hostility, aggression, and suicidal or homicidal ideation” have been observed with misuse. Esketamine nasal spray labeling instructs patients to seek immediate medical help for sudden mood changes, including acting aggressively. Aripiprazole lists homicidal ideation as a rare adverse reaction in adults.
For CCHR, the core issue is that a label does not guarantee patient awareness. This concern has entered public policy. In 2026, Tennessee enacted a law requiring toxicology testing for psychiatric and other drugs following specified violent incidents. CCHR supports similar laws nationwide.
Eastgate stresses that while not all patients will experience these effects, they should be informed. “Prescribers should explain potentially serious violent and suicidal adverse effects—including those considered rare—and document that the patient was given the information necessary to make an informed decision,” she said.
CCHR, established in 1969 by the Church of Scientology and Dr. Thomas Szasz, maintains that transparent disclosure of known risks is fundamental to informed consent. Patients are advised not to abruptly stop taking psychiatric drugs without medical supervision.
